Tumor-infiltrating CD3+ T cells were reduced by approximately 56% and 67% after treatment with chidamide + celecoxib + anti-PD-1 antibody and chidamide + celecoxib, respectively (Fig. 6B; we also showed CD3+ T cells number in SFig. 7A). Here, PDCD1 is linked to neoplasm.